Kaprishi Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-07-2024
- Paid Up Capital ₹ 0.10 M
as on 31-07-2024
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
as on 31-07-2024
- Revenue -76.58%
(FY 2023)
- Profit -72.17%
(FY 2023)
- Ebitda -42.57%
(FY 2023)
- Net Worth 12.41%
(FY 2023)
- Total Assets -16.17%
(FY 2023)
About Kaprishi Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 Cr.
Simanta Barman and Pritikongkana Barman serve as directors at the Company.
- CIN/LLPIN
U52602AS2018PTC018600
- Company No.
018600
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jun 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Guwahati, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Kaprishi Pharma Private Limited offer?
Kaprishi Pharma Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Respiratory Therapy Equipment, Face Mask & Medical PPE Kits, Face Mask, Cosmetics, Hair & Beauty Products, Body Masks, N95 Mask, Venus N95 Mask, Antibiotic Injection, Meropenem Injection.
Who are the key members and board of directors at Kaprishi Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Simanta Barman  | Director | 29-Jun-2018 | Current |
| Pritikongkana Barman | Director | 29-Jun-2018 | Current |
Financial Performance and Corporate Structure Insights of Kaprishi Pharma.
Kaprishi Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 76.58% decrease. The company also saw a substantial fall in profitability, with a 72.17% decrease in profit. The company's net worth Soared by an impressive increase of 12.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kaprishi Pharma?
In 2023, Kaprishi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Assam State Film (Finance & Development )Corporation LtdActive 50 years 3 monthsSimanta Barman is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 Oct 2023 | ₹1.60 Cr | Open |
Others Creation Date: 07 Oct 2023 | ₹4.00 M | Open |
How Many Employees Work at Kaprishi Pharma?
Unlock and access historical data on people associated with Kaprishi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kaprishi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kaprishi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
